跳至主要内容
临床试验/NCT00567801
NCT00567801终止3 期

Prospektive, Randomisierte Multicenter-Studie Zur Optimierung Der Therapie Der Akuten Ischämie Der Unteren Extremitäten Durch Die Kontrollierte Extremitätenreperfusion (Prospective, Randomized Multicenter - Study for Optimization of Therapy of the Acute Ischemic Limb by Controlled Reperfusion)

University Hospital Freiburg23 个研究点 分布在 2 个国家目标入组 250 人开始时间: 2002年9月1日最近更新:
适应症

试验速览

阶段
3 期
状态
终止
发起方
入组人数
250
试验地点
23
主要终点
Amputation-free survival

研究概览

简要总结

The purpose of this study is to prove the findings of a preliminary study which strongly suggest the hypothesis that the result of conventional embolectomy for acute, severe lower-limb ischemia can be improved by controlled reperfusion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 years or older
  • Patients with arterial occlusion of one or both lower limbs with acute decompensated ischemia (Rutherford IIA to III)
  • Informed consent of the patient

排除标准

  • Previous attempt of recanalisation (e.g. lysis therapy)
  • Known A. poplitea aneurysm of the affected extremity
  • Severe heart failure NYHA IV
  • Known atrial thrombus
  • Terminal renal insufficiency (creatinine >10mg/dl or current dialysis therapy, previous transplantation of kidney)
  • Hypersensitivity to allopurinol
  • Hypersensitivity to one component part of the reperfusion solution
  • Participation in a clinical trial during the study or 30 days before
  • Pregnancy or lactation
  • Patient incapable of contracting or not able to understand the character, meaning and consequences of the clinical trial
  • Abuse to drugs or alcohol

结局指标

主要结局

Amputation-free survival

时间窗: 28 days

次要结局

  • Systemic complications in both therapy groups(4 weeks)
  • Tolerance of reperfusion solution(4 weeks)
  • Neurological status (motor function, sensor function) of ischemic limb(4 weeks)
  • Lethality(12 months)

研究者

发起方
University Hospital Freiburg
申办方类型
Other

研究点 (23)

Loading locations...

相似试验